Scarica l'app Stockscreener
27.63
2.26%
-0.64
Dopo l'orario di chiusura:
27.70
0.07
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - Insider Monkey
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors (SMMT) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Stockholders to Reach Out - ACCESS Newswire
10 Stocks Exploding Higher: Bitcoin Miners Dominate the List - Insider Monkey
Summit Therapeutics Jumps 16% On Heavy Volume As Technicals Signal Bullish Breakout - AInvest
Summit Therapeutics Explodes 12%: Legal Probe Ignites Volatility Amid Regulatory Crosshairs - AInvest
Summit Therapeutics Soars 16.5% Amid Regulatory Crossroads and Whale Activity - AInvest
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
H.C. Wainwright Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - WV News
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
10 Stocks Going Wild - Insider Monkey
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal - Insider Monkey
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca - Yahoo Finance
Pomerantz LLP Investigates Claims Against Summit Therapeutics Inc. - AInvest
Summit Therapeutics: A $15B Oncology Gamble with Ivonescimab - AInvest
Summit Therapeutics' $15 Billion Gamble: Balancing Hope and Hurdles in Lung Cancer Therapeutics - AInvest
Summit Therapeutics (NASDAQ:SMMT) Given "Buy" Rating at HC Wainwright - MarketBeat
Why Summit Therapeutics Stock Soared 8% Higher Today - Nasdaq
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment - Benzinga
AstraZeneca Discusses $15 Billion Partnership With Summit Therapeutics, Bloomberg Says, Citing Sources - MarketScreener
Summit climbs on rumour of $15bn AstraZeneca interest - pharmaphorum
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade - Nasdaq
Wall Street Zen Upgrades Summit Therapeutics (NASDAQ:SMMT) to Hold - MarketBeat
Summit Therapeutics (SMMT) Receives 'Buy' Rating from UBS | SMMT Stock News - GuruFocus
Summit Therapeutics (SMMT) Target Price Maintained at $44 by HC Wainwright & Co. | SMMT Stock News - GuruFocus
Revolution Medicines and Summit Therapeutics Announce Clinical Collaboration to Evaluate RAS(ON) Inhibitors in Combination with Ivonescimab for Solid Tumors - Quiver Quantitative
Revolution Medicines Launches Major Cancer Trial: 3 RAS Inhibitors Combined with Novel PD-1 Therapy - Stock Titan
Summit Therapeutics: A Contrarian Play Amid Russell Exclusion and Analyst Divergence? - AInvest
Unlocking Summit Therapeutics' Asymmetric Opportunity: Beyond OS and into Clinical Nuance - AInvest
Summit Therapeutics Breaks Above 200-Day Moving AverageBullish for SMMT - Nasdaq
Summit Therapeutics Signs Sublease with Ascendis Pharma - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit - Bluefield Daily Telegraph
Summit Therapeutics Holds Successful 2025 Annual Meeting - TipRanks
Summit Therapeutics SMMT Sees Institutional Growth on Nasdaq Composite - Kalkine Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - GlobeNewswire Inc.
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partnrs - MarketBeat
Summit Therapeutics (SMMT) Stock Drops After Analyst's Downgrade - GuruFocus
Kalkine : Summit Therapeutics Slides as Nasdaq Index Remains Largely Steady - Kalkine Media
Summit Therapeutics (SMMT) Receives Underperform Rating from Lee - GuruFocus
Why Summit Therapeutics Stock Tanked Today - Barchart.com
U.S. Markets Closed Mixed Wednesday As SailPoint Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Faces Analytical Downgrade on Drug Prospects - GuruFocus
Merck rival Summit draws a rare sell-equivalent rating - Seeking Alpha
Summit Therapeutics (SMMT) Receives New Analyst Coverage from Leerink Partners | SMMT Stock News - GuruFocus
Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target - marketscreener.com
Summit Therapeutics at Goldman Sachs Healthcare Conference: Strategic Advances in Cancer Treatment - Investing.com Canada
Transcript : Summit Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 01 - MarketScreener
Truist Sticks to $35 Target on Summit (SMMT) Despite Shifting Deal Landscape - MSN
Why is Summit stock in selloff after late-stage trial data for lead asset? - MSN
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday - MSN
Wellington Management Group LLP Sells 4,069 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
0.40%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):